What do, can and should we learn from models to evaluate potential anticancer agents?

By Burchill Susan A  

Future Oncology, Vol. 2, Iss. 2, 2006-04 ,pp. : 201-211

Future Medicine

Access to resources Recommend Favorite

What Can We Learn Today?

By Nesland Jahn M.  

Ultrastructural Pathology, Vol. 26, Iss. 3, 2002-05 ,pp. : 123-123

Informa Healthcare

Access to resources Recommend Favorite

Ionising radiation and cancer risks: What have we learned from epidemiology?

By Gilbert Ethel  

International Journal of Radiation Biology, Vol. 85, Iss. 6, 2009-06 ,pp. : 467-482

Informa Healthcare

Access to resources Recommend Favorite

Analysis of Loss of Heterozygosity for Tumor-Suppressor Genes Can Accurately Classify and Predict the Clinical Behavior of Mucinous Tumors Arising From the Appendix

By Maheshwari Vivek   Tsung Allan   Lin Yan   Zeh Herb   Finkelstein Sydney   Bartlett David  

Annals of Surgical Oncology, Vol. 13, Iss. 12, 2006-12 ,pp. : 1610-1616

Springer Publishing Company

Access to resources Recommend Favorite

Borderline Resectable Pancreatic Cancer: What Have We Learned and Where Do We Go From Here?

By Katz Matthew  

Annals of Surgical Oncology, Vol. 18, Iss. 3, 2011-03 ,pp. : 608-610

Springer Publishing Company

Access to resources Recommend Favorite